The combination of CJC-1295 and Ipamorelin has become the most widely used growth hormone research stack for good reason. Each compound targets the GH axis through a distinct mechanism, and their combination produces synergistic GH output that neither can achieve independently.
Growth hormone release from the pituitary gland is controlled by two opposing hypothalamic signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. Natural GH secretion occurs in pulses — primarily during deep sleep — with the amplitude and frequency of these pulses declining significantly with age.
Effective GH research compounds must work within this pulsatile framework. Continuous, non-pulsatile GH elevation (as occurs with direct GH administration) produces different physiological effects and side effect profiles than pulsatile secretion, which is why secretagogues have attracted significant research interest as a more physiologically appropriate approach.
CJC-1295 is a modified GHRH analogue with four amino acid substitutions that make it resistant to DPP-IV enzyme degradation — the primary mechanism that rapidly clears native GHRH from circulation. Additionally, CJC-1295 incorporates a maleimidopropionic acid Drug Affinity Complex (DAC) that enables covalent binding to circulating albumin.
The result is a dramatically extended plasma half-life: native GHRH is cleared within minutes, while CJC-1295 with DAC has a half-life of 6-8 days. This produces sustained, tonic elevation of GH and IGF-1 without requiring frequent administration, making it practical for longer research protocols. Importantly, this sustained GHRH activity does not eliminate pulsatility — it raises the baseline level of GH activity while preserving the pulsatile pattern.
Ipamorelin is a selective pentapeptide ghrelin mimetic that binds to the growth hormone secretagogue receptor (GHSR-1a). Its selectivity is its defining characteristic — unlike GHRP-2 and GHRP-6, which also stimulate cortisol and prolactin release at research-relevant concentrations, Ipamorelin produces GH release with minimal off-target receptor activation.
At research concentrations, Ipamorelin does not produce measurable cortisol or prolactin elevation, making it a cleaner tool for isolating GH-specific effects. It also works through a completely different mechanism from CJC-1295 — it acts on the ghrelin receptor rather than the GHRH receptor, meaning the two compounds address the GH axis through independent, additive pathways.
When CJC-1295 and Ipamorelin are used in combination, they produce GH output that exceeds either compound alone. CJC-1295 provides sustained GHRH receptor stimulation, which primes the somatotroph cells of the pituitary for maximum GH output. Ipamorelin then triggers acute GH pulses through GHSR-1a activation at the same primed cells, with the result being higher amplitude pulses than Ipamorelin can produce without the CJC-1295 priming effect.
Additionally, Ipamorelin's mechanism partially overcomes somatostatin-mediated inhibition — something CJC-1295 cannot do — further enhancing GH pulse amplitude. The combination therefore addresses both the stimulatory and inhibitory sides of GH regulation simultaneously.
Both compounds should be reconstituted in bacteriostatic water. CJC-1295 is stable for up to 20 days at 4°C post-reconstitution; Ipamorelin for up to 10 days. Both are available from SyntheticLabs at 99.7% and 99.5% purity respectively, with batch-specific CoA documentation.